[Form 4] BeOne Medicines Ltd. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. reported a compensation-related equity grant linked to its board. On June 11, 2026, the company granted 18,980 restricted share units payable solely in ordinary shares to Felix J. Baker in connection with his election to the board under the 2016 Share Option and Incentive Plan. The RSUs vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service. Due to the Baker Bros. fund structure, the RSU grant and resulting ordinary shares are reflected as indirect proportionate pecuniary interests of affiliated funds, with investment adviser Baker Bros. Advisors LP holding voting and dispositive power. The filing also notes indirect and direct holdings of American Depositary Shares, with each ADS representing 13 ordinary shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN
Role
null | null | null | null | null | null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Ordinary Shares | 18,980 | $0.00 | -- |
| Grant/Award | Ordinary Shares | 18,980 | $0.00 | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | American Depositary Shares | -- | -- | -- |
| holding | American Depositary Shares | -- | -- | -- |
| holding | American Depositary Shares | -- | -- | -- |
| holding | American Depositary Shares | -- | -- | -- |
Holdings After Transaction:
Ordinary Shares — 161,546 shares (Indirect, See Footnotes);
Ordinary Shares — 1 shares (Direct, null);
American Depositary Shares — 10,418 shares (Direct, null);
American Depositary Shares — 730,642 shares (Indirect, See Footnotes)
Footnotes (1)
- On June 11, 2026, BeOne Medicines Ltd. (the "Issuer") granted 18,980 restricted share units (each an "RSU") payable solely in ordinary shares ("Ordinary Shares") to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") in conjunction with his election to the board of directors of the Issuer (the "Board") pursuant to the Issuer's 2016 Share Option and Incentive Plan, as amended (the "2016 Plan"). The RSUs vest on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting of the Issuer, provided, however, that all vesting of RSUs granted to a director shall cease if that director resigns from the Board or otherwise ceases to serve as a director, unless the Board determines otherwise. After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Ordinary Shares reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds (as defined below) are entitled to an indirect proportionate pecuniary interest in such securities. The Funds (as defined below) each own an indirect proportionate pecuniary interest in the Ordinary Shares received upon vesting of RSUs received as a result of his service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds (as defined below) and (ii) the Funds (as defined below), Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Ordinary Shares received upon vesting of RSUs, non-qualified share options convertible solely into Ordinary Shares of the Issuer ("Share Options"), and Ordinary Shares received upon the exercise of Share Options (i.e., no direct pecuniary interest). The Adviser serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Ordinary Shares received as a result of the exercise of Share Options or vesting of RSUs. The acquisitions of the RSUs on this form represent a grant to Felix J. Baker of 18,980 RSUs. This grant of 18,980 RSUs for Felix J. Baker is reported for each of the Funds as each has an indirect proportionate pecuniary interest in such securities. Felix J. Baker serves on the Board as a representative of the Funds and their affiliates and control persons. Includes beneficial ownership of 71,279 Ordinary Shares received from vested RSUs previously granted to Michael Goller, and 71,266 Ordinary Shares received from vested RSUs previously granted to Ranjeev Krishana, in their capacity as directors of the Issuer. After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Ordinary Shares reported in column 5 of Table I directly held by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. Ordinary Share held directly by Felix J. Baker. Ordinary Share held directly by Julian C. Baker. Each ADS represents 13 Ordinary Shares. American Depositary Shares held directly by Felix J. Baker. American Depositary Shares held directly by Julian C. Baker. As a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. As a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
Key Figures
RSU grant size: 18,980 RSUs
Indirect ordinary shares after grant (entry 1): 161,550 ordinary shares
Indirect ordinary shares after grant (entry 2): 161,546 ordinary shares
+5 more
8 metrics
RSU grant size
18,980 RSUs
Granted June 11, 2026 for board service
Indirect ordinary shares after grant (entry 1)
161,550 ordinary shares
Total shares following RSU-related transaction, indirect
Indirect ordinary shares after grant (entry 2)
161,546 ordinary shares
Total shares following RSU-related transaction, indirect
ADS held indirectly (667 or fund)
8,068,411 ADS
Total American Depositary Shares following transaction
ADS held indirectly (second fund)
730,642 ADS
Total American Depositary Shares following transaction
ADS held directly per Baker
10,418 ADS
Direct ADS position reported after transaction
Ordinary shares per ADS
13 ordinary shares per ADS
Stated ADS-to-ordinary share ratio
Transaction price per RSU
$0.00 per share
Equity grant with no cash consideration
Key Terms
restricted share units, indirect proportionate pecuniary interest, American Depositary Shares, non-qualified share options, +1 more
5 terms
indirect proportionate pecuniary interest financial
"each may be deemed to have an indirect pecuniary interest in the Ordinary Shares"
voting and dispositive power financial
"the Adviser has voting and dispositive power over the Share Options, RSUs and any Ordinary Shares"
FAQ
What equity award did BeOne Medicines (ONC) disclose for Felix J. Baker?
BeOne Medicines disclosed a grant of 18,980 restricted share units payable in ordinary shares to Felix J. Baker. The award was made in connection with his election to the board under the company’s 2016 Share Option and Incentive Plan.
When do the 18,980 RSUs granted by BeOne Medicines to Felix J. Baker vest?
The 18,980 RSUs vest on the earlier of the first anniversary of the June 11, 2026 grant date or the date of the next annual general meeting. Vesting generally requires that Felix J. Baker continue serving as a director on the board.
Do Felix and Julian Baker claim full beneficial ownership of BeOne Medicines securities?
No. The filing states that Julian C. Baker, Felix J. Baker, the adviser and its general partner disclaim beneficial ownership of securities held for the funds, except to the extent of their pecuniary interest, limiting their reported ownership for Section 16 purposes.